NEW YORK — Genetic Technologies said on Wednesday that it has acquired the distribution rights to Taliaz's Predictix line of antidepressant drug selection tools in Australia, New Zealand, and the US.
According to Taliaz, the products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions. The Tel Aviv, Israel-based company currently offers Predictix Digital, which focuses on clinical and demographic data, and Predictix Genetics, which uses genetic testing data.